Related Experiment Video
Updated: Jan 6, 2026
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management
Satish S C Rao1, Jigar Bhagatwala1
1Augusta University, Augusta, Georgia, USA.
Abstract:
Small intestinal bacterial overgrowth (SIBO) is a common, yet underrecognized, problem. Its prevalence is unknown because SIBO requires diagnostic testing. Although abdominal bloating, gas, distension, and diarrhea are common symptoms, they do not predict positive diagnosis. Predisposing factors include proton-pump inhibitors, opioids, gastric bypass, colectomy, and dysmotility. Small bowel aspirate/culture with growth of 10-10 cfu/mL is generally accepted as the "best diagnostic method," but it is invasive. Glucose or lactulose breath testing is noninvasive but an indirect method that requires further standardization and validation for SIBO. Treatment, usually with antibiotics, aims to provide symptom relief through eradication of bacteria in the small intestine. Limited numbers of controlled studies have shown systemic antibiotics (norfloxacin and metronidazole) to be efficacious. However, 15 studies have shown rifaximin, a nonsystemic antibiotic, to be effective against SIBO and well tolerated. Through improved awareness and scientific rigor, the SIBO landscape is poised for transformation.
Insights
Small intestinal bacterial overgrowth (SIBO) is a common gastrointestinal issue. Rifaximin shows promise as an effective and well-tolerated treatment for SIBO, potentially transforming patient care.
Area of Science:
- Gastroenterology
- Microbiology
- Internal Medicine
Background:
- Small intestinal bacterial overgrowth (SIBO) is prevalent but often underdiagnosed.
- Symptoms like bloating and diarrhea are common but not diagnostic.
- Risk factors include PPIs, opioids, surgery, and motility disorders.
Purpose of the Study:
- To review the diagnostic challenges and treatment options for SIBO.
- To evaluate the efficacy and tolerability of rifaximin for SIBO.
- To highlight the potential for improved SIBO diagnosis and management.
Main Methods:
- Review of diagnostic methods including invasive small bowel culture and noninvasive breath tests.
- Analysis of existing studies on antibiotic treatments for SIBO.
- Evaluation of data on rifaximin's effectiveness and safety.
Main Results:
- Small bowel aspirate/culture is the gold standard but invasive.
- Breath tests are noninvasive but require standardization.
- Systemic antibiotics have shown efficacy, but rifaximin is effective and well-tolerated.
Conclusions:
- SIBO diagnosis requires specific testing beyond symptom presentation.
- Rifaximin offers a promising, non-systemic antibiotic treatment option for SIBO.
- Increased awareness and research are crucial for advancing SIBO management.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...